ClosedSuppliesEuropeanOnderhandeling zonder bekendmaking

Voluntary transparency Immunostainers and ready-to-use antibodies including maintenance

Universitair Medisch Centrum Utrecht · Onderhandeling zonder bekendmaking · 1 lots · 222318
Type
Supplies
38900000
Estimated value
Not published
To deadline
Ongoing
Knock-outs
n/a
exclusion grounds
Award basis
Best price-quality ratio
Assess manuallyconfidence low

University Medical Center Utrecht (UMC Utrecht) intends to purchase five BenchMark Ultra® systems to cover the growing immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) workload. The current four systems have reached end-of-life and can no longer meet the requirements for protocol freedom, dual chromogenic ISH, and the use of Ready-To-Use (RTU) antibodies. The tender also includes a maintenance contract, disposables, and RTU antibodies. Market research shows that no other systems with comparable functionality are available, meaning competition is technically lacking. The procedure is a negotiation without publication, focused on one care process and one contract. The focus lies on technical compatibility, process efficiency, and the continuity of the diagnostic workflow.

Supplies · Onderhandeling zonder bekendmaking · European procedure

European
Contract type
Supplies
Onderhandeling zonder bekendmaking
Estimated value
Estimate not published
Submission deadline
Ongoing
Scope
European
European procedure
Lots
1
1 lots
Main CPV code
Location
Utrecht
CharacteristicsCPV 38SuppliesEU tenderBenchMark UltraimmunohistochemistryCISH

01What is being requested

University Medical Center Utrecht (UMC Utrecht) intends to purchase five BenchMark Ultra® systems to cover the growing immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) workload. The current four systems have reached end-of-life and can no longer meet the requirements for protocol freedom, dual chromogenic ISH, and the use of Ready-To-Use (RTU) antibodies. The tender also includes a maintenance contract, disposables, and RTU antibodies. Market research shows that no other systems with comparable functionality are available, meaning competition is technically lacking. The procedure is a negotiation without publication, focused on one care process and one contract. The focus lies on technical compatibility, process efficiency, and the continuity of the diagnostic workflow.

The Pathology department has experienced production growth in the number of samples offered over the past few years. This growth also leads to an increase in the number of immunohistochemical stains. To accommodate this production growth and achieve process efficiency, the pathology department intends to proceed with the purchase of an additional fifth BenchMark Ultra® system and to replace the current four machines because they are end-of-life. The contract consists in total of 5 BenchMark Ultra® systems, a maintenance contract, disposables, and Ready-To-Use (RTU) antibodies. It concerns one

38900000Supplies
1Lot 1

02Exclusion grounds

Exclusion grounds — consult the ESPD
  • No specific exclusion grounds were extracted. In a European tender, the mandatory and discretionary grounds of art. 2.86/2.87 of the Dutch Procurement Act almost always apply — check the European Single Procurement Document (ESPD).

03Value in context

Estimate not published

The contracting authority did not publish an estimated value — common for a large share of contracts. The EU threshold for leveringen is € 221.000, for reference.

04Likely competitors

#Likely bidderFitWins
1Agilent Technologies Netherlands B.V.SME7910×
2Bruker Nederland B.V.SME7613×
3Waters Chromatography B.V.SME7612×
4Carl Zeiss B.V.SME7210×
5FEI Europe B.V.SME69
6OncoMed-SolutionsUnknown66

05Legal themes that may be relevant here

06Frequently asked questions

What is the specific scope of the contract for the Pathology department?
The contract includes the supply of a total of 5 BenchMark Ultra® systems, including a maintenance contract, disposables, and Ready-To-Use (RTU) antibodies.
Why was this specific equipment chosen?
The current four systems are end-of-life. The new systems are required to accommodate the growth in immunohistochemical stains and to increase process efficiency.
Which technical requirements are important for the care process?
The systems must provide protocol freedom, dual chromogenic ISH, and the use of Ready-To-Use (RTU) antibodies, whereby continuous loading per individual slide and pretreatment per slide must be possible.
Why is there a lack of competition?
Market research shows that no other reasonable alternatives exist that meet the requirements regarding the entire care process concerning immunohistochemistry and CISH within the pathology of UMC Utrecht.

Automatically compiled from the official tender data and documents.

07Estimated value versus the market

p25
€ 300K
median
€ 515K
p75
€ 1,7 mln
deze opdracht

Gegunde waarden in CPV 38 · leveringen n=331